StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 7.7 %
EVOK stock opened at $0.51 on Friday. The business has a 50 day moving average of $0.49 and a 200 day moving average of $0.64. The firm has a market cap of $4.37 million, a PE ratio of -0.28 and a beta of 0.38. Evoke Pharma has a twelve month low of $0.40 and a twelve month high of $1.77.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. The company had revenue of $1.74 million during the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Why is the Ex-Dividend Date Significant to Investors?
- RXO Shares Surge Following New Acquisition Deal
- 5 discounted opportunities for dividend growth investors
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- The 3 Best Fintech Stocks to Buy Now
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
